ANTI-CD3 ANTIBODIES AND METHODS OF USE

FIELD OF THE INVENTION

The present invention relates to anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

BACKGROUND

Cell proliferative disorders, such as cancer, are characterized by the uncontrolled growth of cell subpopulations. They are the leading cause of death in the developed world and the second leading cause of death in developing countries, with over 12 million new cancer cases diagnosed and 7 million cancer deaths occurring each year. The National Cancer Institute estimates that greater than half a million Americans will die of cancer in 2013, accounting for nearly one out of every four deaths in the country. As the elderly population has grown, the incidence of cancer has concurrently risen, as the probability of developing cancer is more than two-fold higher after the age of seventy. Cancer care thus represents a significant and ever-increasing societal burden.

Longstanding approaches to cancer treatment include chemotherapy, radiation therapy, and surgery to remove solid tumors. Recently, bispecific antibody-based immunotherapies have been developed. Such bispecific antibodies are capable of simultaneously binding cell surface antigens on cytotoxic cells and tumor cells, with the intent that the bound cytotoxic cell will destroy the bound tumor cell. Existing bispecific antibodies currently undergoing clinical trials for treating cancer are limited by their short half-lives and/or variable efficacy. Thus, there is an unmet need in the field for the development of effective bispecific antibodies for use in cancer treatment.

SUMMARY

The present ~~invention~~ disclosure relates to anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

In one aspect, ~~the invention features~~there is provided an anti-cluster of differentiation 3 (CD3) antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six hypervariable regions (HVRs): (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185. In some embodiments, the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 184; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 184. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 185. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 186 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 187. In some embodiments, the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID

NO: 186; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 186. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 187.

In one aspect, ~~the invention features~~there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of $X_1X_2YSX_3X_4X_5FDY$, wherein X_1 is selected from the group consisting of D, T, and S; X_2 is selected from the group consisting of G, A, and S; X_3 is R or N; X_4 is Y or A; and X_5 is Y or A (SEQ ID NO: 181); (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of $X_1X_2SX_3X_4LRT$, wherein X_1 is K or T; X_2 is Q or A; X_3 is F or A; and X_4 is I or A (SEQ ID NO: 182). In some embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 188 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 189. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 188. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 189.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 13; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 190 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 191. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 191; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 190. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 191.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 192 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 193. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid

sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 193; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 192. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 193.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 15. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 194 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 195. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 194; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 195; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 194. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 195.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 16. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 196 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 197. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 197; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 196. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 197.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 198 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 199. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 198. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 199.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid

sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 18; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 200 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 201. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 200; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 201; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 200. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 201.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 19; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 202 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 203. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 202; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 203; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 202. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 203.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 20; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 204 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 205. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 204; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 204. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 205.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 21; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 206 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 207. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207; or (c) a VH domain as in (a) and a VL domain as in (b). In some

embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 206. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 207.

~~In some aspects, the invention features~~Disclosed is an anti-CD3 antibody comprising a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 188 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 189; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 190 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 191; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 192 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 193; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 194 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 195; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 196 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 197; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 198 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 199; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 200 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 201; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 202 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 203; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 204 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 205; or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 206 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 207.

In ~~some~~ another aspects, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of LINPYKGVX$_1$TYX$_2$X$_3$X$_4$X$_5$KX$_6$, wherein X$_1$ is S or T; X$_2$ is N or A; X$_3$ is Q or D; X$_4$ is K or S; X$_5$ is F or V; and X$_6$ is D or G (SEQ ID NO: 183); (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In some embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 208 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 209. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 208. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 209.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d)

an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 210 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 211. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 210. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 211.

In other embodiments, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 212 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 213. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 212; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 212. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 213.

~~In some aspects, the invention features~~Disclosed is an anti-CD3 antibody comprising a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 208 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 209; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 210 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 211; or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 212 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 213.

In ~~some~~ another aspects, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 31; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 33; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 34; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 36. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 214 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 215. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 214; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 214. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 215. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 216 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 217. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 216; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 217; or (c) a VH

domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 216. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 217.

~~In some aspects, the invention features~~ Disclosed is an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 214 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 215, or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 216 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 217.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 37; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 38; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 40; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 41; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 42. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 218 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 219. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 219; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 218. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 219. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 220 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 221. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 220; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 221; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 220. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 221.

~~In some aspects, the invention features~~ Disclosed is an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 218 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 219, or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 220 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 221.

In ~~some~~ another aspect~~s~~, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 43; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 44; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 46; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 47; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 48. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 222 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 223. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of

SEQ ID NO: 223; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 222. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 223. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 224 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 225. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 224; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 225; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 224. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 225. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 226 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 227. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 226; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of *SEQ ID NO: 226*. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 227.

~~In some aspects, the invention features~~Disclosed is an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 222 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 223; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 224 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 225; (a) a VH domain comprising an amino acid sequence of SEQ ID *NO: 226 and (b) a VL domain comprising an amino acid sequence of* SEQ ID NO: 227.

In another~~some~~ aspects, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 49; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 50; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 51; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 52; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 54. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 228 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 229. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 228; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 229; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 228. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 229. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 230 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 231. *In some embodiments, the binding domain comprises (a) a VH domain comprising an* amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 230; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 230. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 231.

~~In some aspects, the invention features~~Disclosed is an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID

NO: 228 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 229, or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 230 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 231.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 55; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 56; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 57; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 59; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 232; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 233; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 232. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 233.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 232 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 233.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 61; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 62; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 64; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 65; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 66. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 234; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 235; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 234. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 235.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 234 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 235.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 67; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 69; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 70; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 72. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence

having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 236; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 237; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 236. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 237.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 236 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 237.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 73; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 74; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 75; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 76; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 77; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 238; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 239; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 238. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 239.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 238 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 239.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 79; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 80; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 81; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 82; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 83; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 240; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 241; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 240. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 241.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 240 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 241.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino

acid sequence of SEQ ID NO: 85; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 86; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 87; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 88; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 89; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 90. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 242; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 243; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 242. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 243.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 242 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 243.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 91; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 92; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 93; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 94; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 95; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 96. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 244; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 245; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 244. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 245.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 244 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 245.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 97; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 98; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 99; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 100; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 101; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 102. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 246; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 247; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 246. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 247.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 246 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 247.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 103; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 104; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 105; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 106; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 107; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 108. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 248; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 249; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 248. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 249.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 248 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 249.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 109; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 110; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 111; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 112; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 113; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 114. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 250; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 251; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 250. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 251.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 250 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 251.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 117; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 120. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence

having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 252; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 253; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 252. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 253.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 252 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 253.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 121; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 122; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 123; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 124; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 125; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 126. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 254; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 255; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 254. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 255.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 254 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 255.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 127; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 128; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 129; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 130; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 131; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 132. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 256; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 257; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 256. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 257.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 256 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 257.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino

acid sequence of SEQ ID NO: 133; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 134; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 135; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 136; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 137; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 138. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 258; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 259; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 258. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 259.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 258 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 259.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 139; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 140; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 141; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 142; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 143; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 144. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 260; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 261; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 260. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 261.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 260 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 261.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 145; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 146; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 147; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 148; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 149; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 150. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 262; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 263; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 262. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 263.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 262 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 263.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 151; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 152; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 153; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 154; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 155; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 156. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 264; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 265; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 264. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 265.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 264 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 265.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3. In certain ~~aspects~~embodiments, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope further comprises one or more additional amino acid residues selected from the group consisting of Gln1, Asp2, and Met7 of CD3. In a further ~~aspect~~embodiment, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope comprises amino acid residues Gln1, Asp2, and Glu6 of CD3. In certain ~~aspect~~embodiments, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope comprises amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3. In another ~~aspect~~embodiment, the ~~invention~~*disclosure features an anti-CD3 antibody, wherein the epitope does not comprise amino acid* residue Glu5 of CD3. In a further ~~aspect~~embodiment, the disclosure~~invention~~ features an anti-CD3 antibody, wherein the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3. In certain ~~aspect~~embodiments, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope consists of amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

In related ~~aspects~~embodiments, the ~~invention~~disclosure features an anti-CD3 antibody that binds such an epitope and that is a multispecific antibody. In some embodiments, the multispecific antibody is a bispecific antibody. In some embodiments, the bispecific antibody comprises a second binding domain that binds to a second biological molecule, wherein the second biological molecule is a cell surface antigen. In some embodiments, the cell surface antigen is a tumor antigen. In some embodiments, the tumor antigen is selected from the group consisting of CD20; FcRH5 (Fc Receptor-like 5); HER2; LYPD1; Ly6G6D (lymphocyte antigen 6 complex, locus G61); Ly6-D, MEGT1); PMEL17 (silver homolog; SILV; D12S53E; PMEL17; (SI); (SIL); ME20; gp100); Ly6E (lymphocyte antigen 6 complex, locus E; Ly67, RIG-E, SCA-2, TSA-1); CD19; CD33; CD22 (B-cell receptor CD22-B isoform); CD79a (CD79A, CD79a, immunoglobulin-associated alpha; BMPR1B (bone morphogenetic protein receptor-type IB); CD79b (CD79B, CD79β, 1 Gb (immunoglobulin-associated beta), B29); EDAR (Ectodysplasin A Receptor); GFRA1 (GDNF-Ra1);

SNRPD1; SOX10; Sp17; SSX-2; SSX-4; STEAP1; survivin; SYT-SSX1 or -SSX2 fusion protein; TAG-1; TAG-2; Telomerase; TGF-betaRII; TRAG-3; Triosephosphate isomerase; TRP-1 / gp75; TRP-2; TRP2-INT2; tyrosinase; VEGF; WT1; XAGE-1b/GAGED2a; and SLC35D3. In some embodiments, the tumor antigen is selected from the group consisting of CD20, FcRH5, HER2, LYPD1, LY6G6D, PMEL17, LY6E, CD19, CD33, CD22, CD79A, CD79B, EDAR, GFRA1, MRP4, RET, Steap1, and TenB2.

In some embodiments, the tumor antigen is CD20 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267. In some embodiments, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 266; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 267; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 266. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 267.

In some embodiments, the tumor antigen is FcRH5 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 163; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 164; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 165; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 166; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 168. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 268 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 269. In some embodiments, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 268; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 269; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 268. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 269.

In some embodiments, the tumor antigen is HER2 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 169; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 170; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 171; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 172; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 173; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 174. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 270 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 271. In some embodiments, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 270; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 271; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the

amino acid sequence of SEQ ID NO: 270. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 271.

In some embodiments, the tumor antigen is HER2 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 581; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 582; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 583; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 584; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 585; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 586. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 593 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 594. In some embodiments, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 593; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 594; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 593. In some embodiments the VL domain comprises the amino acid sequence of SEQ ID NO: 594.

In some embodiments, the tumor antigen is HER2 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 587; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 588; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 589; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 590; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 591; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 592. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 595 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 596. In some embodiments, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 595; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 596; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 595. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 596.

In some embodiments, the tumor antigen is RET and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 613; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 614; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 615; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 616; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 617; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 618. In some embodiments, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 619; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 620; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 619. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 620.

In some embodiments, the tumor antigen is LYPD1 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 175; (b) an

HVR-H2 comprising the amino acid sequence of SEQ ID NO: 176; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 177; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 178; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 179; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 180. In another aspect, there is provided an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 272 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 273. In some embodiments, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 272; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 273; or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 272. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 273.

In some ~~aspects~~embodiments, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 268 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 269; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 270 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 271; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 272 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 273; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 593 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 594; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 595 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 596; or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 619 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 620.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and an anti-CD20 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein the anti-CD3 antibody comprises an N297G substitution mutation.

In another aspect, there is provided ~~invention features~~ an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein (a) the anti-CD3 arm comprises T366S, L368A, Y407V, and N297G substitution mutations and (b) the anti-CD20 arm comprises T366W and N297G substitution mutations.

In some embodiments, any one of the preceding anti-CD3 antibodies can comprise one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 ($CH1_1$) domain, a first CH2 ($CH2_1$) domain, a first CH3 ($CH3_1$) domain, a second CH1 ($CH1_2$) *domain, second CH2 ($CH2_2$) domain, and a second CH3 ($CH3_2$) domain. In some embodiments, at least* one of the one or more heavy chain constant domains is paired with another heavy chain constant domain. In some embodiments, the $CH3_1$ and $CH3_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH3_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH3_2$ domain. In some embodiments, the $CH3_1$ and $CH3_2$ domains meet at an interface between said protuberance and cavity. In some embodiments, the $CH2_1$ and $CH2_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH2_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH2_2$ domain. In some embodiments, the $CH2_1$ and $CH2_2$ domains meet at an interface between said protuberance and cavity.

In some embodiments, the half-life of any one of the preceding anti-CD3 antibodies may be about 7 days.

In another aspect, there is provided an immunoconjugate comprising the anti-CD3 antibody described herein and a cytotoxic agent. In some embodiments, the ~~invention~~ disclosure features an immunoconjugate comprising any one of the preceding anti-CD3 antibodies conjugated to a cytotoxic agent. ~~Also~~ In another aspect, there is provided ~~is~~ a composition comprising any one of the preceding anti-CD3 antibodies. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent. In another ~~aspect~~embodiment, the ~~invention~~disclosure features an isolated nucleic acid that encodes any of the anti-CD3 antibodies disclosed herein, comprising a vector (e.g., an expression vector) for expressing the antibody. In another aspect, there is provided an isolated nucleic acid encoding the anti-CD3 antibody described herein. In another aspect, there is provided a vector comprising the isolated nucleic acid described herein.

In another ~~aspect~~embodiment, the ~~invention~~disclosure features host cells comprising the preceding nucleic acids and/or vectors. In another aspect, there is provided a host cell comprising the vector described herein. In some embodiments, the host cell is a mammalian cell (e.g., a Chinese hamster ovary (CHO) cell). In other embodiments, the host cell is a prokaryotic cell (e.g., an *E. coli* cell). In another aspect, there is provided a method of producing the anti-CD3 antibody described herein, the method comprising culturing the host cell described herein in a culture medium. A

method of producing any one of the preceding anti-CD3 antibodies is also provided, the method comprising culturing the host cell that produces the anti-CD3 antibody and recovering the anti-CD3 antibody from the host cell or the culture medium.

In another aspect, there is provided use of any one of the anti-CD3 antibody described herein for use as a medicament. In some ~~aspects~~embodiments, any one of the preceding anti-CD3 antibodies can be for use as a medicament. In some embodiments, any one of the preceding anti-CD3 antibodies can be for use in treating or delaying progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof. In some embodiments, any one of the preceding anti-CD3 antibodies can be for use in enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

In another aspect, there is provided use of the anti-CD3 antibody described herein in the manufacture of a medicament for treating or delaying progression of a cell proliferative disorder or an autoimmune disorder in a subject. In some ~~aspects~~embodiments, the ~~invention~~disclosure features the use of any one of the preceding anti-CD3 antibodies in the manufacture of a medicament for treating or delaying progression of a cell proliferative disorder or an autoimmune disorder. In another~~some~~ aspects, there is provided ~~invention features~~ the use of any one of the preceding anti-CD3 antibodies in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

A further ~~aspect~~ embodiment of the disclosure~~invention~~ is a method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject an effective amount any one of the preceding anti-CD3 antibodies. In another ~~aspect~~embodiment, the disclosure~~invention~~ features a method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject any one of the preceding anti-CD3 antibodies. In some embodiments, the anti-CD3 antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a second biological molecule located on a target cell other than the immune effector cell. In some *embodiments, the anti-CD3 antibody activates the immune effector cell following binding to (a) and (b). In* some embodiments, the activated immune effector cell is capable of exerting a cytotoxic effect and/or an apoptotic effect on the target cell. In some embodiments, the anti-CD3 antibody is administered to the subject in a dosage of about 0.01 mg/kg to about 10 mg/kg. In some embodiments, the anti-CD3 antibody is administered to the subject in a dosage of about 0.1 mg/kg to about 10 mg/kg. In some embodiments, the anti-CD3 antibody is administered to the subject in a dosage of about 1 mg/kg. In some embodiments, the anti-CD3 antibody is administered subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In some embodiments, the anti-CD3 antibody is administered subcutaneously. In some embodiments, the anti-CD3 antibody is administered intravenously.

In some embodiments, the method further comprises administering to the subject a PD-1 axis binding antagonist or an additional therapeutic agent. In some embodiments, the additional therapeutic agent is administered prior to or subsequent to the administration of the anti-CD3 antibody. In some embodiments, the additional therapeutic agent is administered concurrently with the anti-CD3 antibody. In some embodiments, the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist. In some embodiments, the PD-1 axis binding antagonist is a PD-1 binding antagonist. In some embodiments, the PD-1 binding antagonist is selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), CT-011 (pidilizumab), and AMP-224. In other embodiments, the PD-1 axis binding antagonist is a PD-L1

binding antagonist. In some embodiments, the PD-L1 binding antagonist is selected from the group consisting of: YW243.55.S70, MPDL3280A, MDX-1105, and MEDI4736. In other embodiments, the PD-1 axis binding antagonist is a PD-L2 binding antagonist. In some embodiments, the PD-L2 binding antagonist is an antibody or an immunoadhesin.

In another aspect, there is provided use of an anti-CD3 antibody in the manufacture of a medicament for treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof , wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm and wherein the medicament is formulated for administration with a PD-1 axis binding antagonist. In another aspect, there is provided use of an anti-CD3 antibody in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm and wherein the medicament is formulated for administration with a PD-1 axis binding antagonist. In some ~~aspects~~embodimentss, the ~~invention~~disclosure features a method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm. In some ~~aspect~~embodiments, the ~~invention~~disclosure features a method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm (i.e., a CD20 TDB). In some embodiments, (a) the anti-CD3 arm comprises a first binding domain comprising (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 184, and (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 185; (b) the anti-CD20 arm comprises a second binding domain comprising (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 266, and (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 267; and/or (c) the PD-1 axis binding antagonist is an anti-PD-L1 antibody.

In some embodiments, the anti-CD3 antibody comprises an anti-CD20 arm comprising a N297G substitution mutation. In some embodiments, the anti-CD3 antibody comprises an anti-CD3 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-CD20 arm comprising T366W and/or N297G substitution mutation(s). In some embodiments, the anti-CD3 antibody comprises an anti-CD3 arm comprising a N297G substitution mutation. In some embodiments, the anti-CD3 antibody comprises an anti-CD20 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-CD3 arm comprising T366W and/or N297G substitution mutation(s).

In some embodiments, the anti-CD3 antibody comprises an anti-HER2 arm comprising a N297G substitution mutation. In some embodiments, the anti-CD3 antibody comprises an anti-CD3 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-HER2 arm comprising N297G, N297A, L234A, L235A, and/or D265A substitution mutation(s). In some embodiments, the anti-CD3 antibody comprises an anti-CD3 arm comprising a N297G substitution mutation. In some embodiments, the anti-CD3 antibody comprises an anti-HER2 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-CD3 arm comprising N297G, N297A, L234A, L235A, and/or D265A substitution mutation(s).

In some embodiments, the method further comprises administering to the subject a *glucocorticoid. In some embodiments, the glucocorticoid is selected from the group consisting of* dexamethasone, hydrocortisone, cortisone, prednisolone, prednisone, methylprednisone, triamcinolone, paramethasone, betamethasone, fludrocortisone, and pharmaceutically acceptable esters, salts, and complexes thereof. In some embodiments, the glucocorticoid is dexamethasone. In some embodiments, the glucocorticoid is a pharmaceutically acceptable ester, salt, or complex of dexamethasone.

In some embodiments, the method further comprises administering to the subject rituximab.

In some embodiments, the method further comprises administering to the subject obinutuzumab.

In some embodiments, the method further comprises administering to the subject an antibody-drug conjugate (ADC).

In any of the preceding uses or methods, the cell proliferative disorder can be cancer. In some embodiments, the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In some embodiments, the preferred cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL)

In any of the preceding uses or methods, the autoimmune disorder can be selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

In another aspect, there is provided a kit comprising: (a) the composition of any one of preceding anti-CD3 antibodies; and (b) a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder or an autoimmune disorder. In another ~~aspect~~embodiment, the ~~invention~~ disclosure features a kit comprising: (a) a composition comprising any one of the preceding anti-CD3 antibodies and (b) a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder.

In any of the preceding uses or methods, the subject can be a human.

WHAT IS CLAIMED IS:

1. An anti-cluster of differentiation 3 (CD3) antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

2. The anti-CD3 antibody of claim 1, wherein the binding domain is selected from a group consisting of (i) a binding domain comprising (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 184; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185; or (c) a VH domain as in (a) and a VL domain as in (b); and (ii) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 186; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187; or (c) a VH domain as in (a) and a VL domain as in (b).

3. The anti-CD3 antibody of claim 2(i), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 184; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 185.

4. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185.

5. The anti-CD3 antibody of claim 2(ii), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 186; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 187.

6. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 186 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 187.

7. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of $X_1X_2YSX_3X_4X_5FDY$, wherein X_1 is selected from the group consisting of D, T, and S; X_2 is selected from the group consisting of G, A, and S; X_3 is R or N; X_4 is Y or A; and X_5 is Y or A (SEQ ID NO: 181);

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of $X_1X_2SX_3X_4LRT$, wherein X_1 is K or T; X_2 is Q or A; X_3 is F or A; and X_4 is I or A (SEQ ID NO: 182).

8. The anti-CD3 antibody of claim 7, wherein the binding domain is selected from a group consisting of

(i) a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12;

(ii) a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 13;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12;

(iii) a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14;

(iv) a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

(v) a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 16;

(vi) a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12;

(vii) a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 18;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12;

(viii) a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 19;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12;

(ix) a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 20;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12;

and

(x) a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22;

9. The anti-CD3 antibody of claim 8(i), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189; or (c) a VH domain as in (a) and a VL domain as in (b).

10. The anti-CD3 antibody of claim 9, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 188; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 189.

11. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 188 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 189.

12. The anti-CD3 antibody of claim 8(ii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 191; or (c) a VH domain as in (a) and a VL domain as in (b).

13. The anti-CD3 antibody of claim 12, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 190; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 191.

14. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 190 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 191.

15. The anti-CD3 antibody of claim 8(iii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 193; or (c) a VH domain as in (a) and a VL domain as in (b).

16. The anti-CD3 antibody of claim 15, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 192; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 193.

17. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 192 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 193.

18. The anti-CD3 antibody of claim 8(iv), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 194; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 195; or (c) a VH domain as in (a) and a VL domain as in (b).

19. The anti-CD3 antibody of claim 18, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 194; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 195.

20. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 194 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 195.

21. The anti-CD3 antibody of claim 8(v), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 197; or (c) a VH domain as in (a) and a VL domain as in (b).

22. The anti-CD3 antibody of claim 21, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 196; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 197.

23. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 196 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 197.

24. The anti-CD3 antibody of claim 8(vi), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199; or (c) a VH domain as in (a) and a VL domain as in (b).

25. The anti-CD3 antibody of claim 24, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 198; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 199.

26. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 198 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 199.

27. The anti-CD3 antibody of claim 8(vii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 200; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 201; or (c) a VH domain as in (a) and a VL domain as in (b).

28. The anti-CD3 antibody of claim 27, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 200; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 201.

29. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 200 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 201.

30. The anti-CD3 antibody of claim 8(viii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 202; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 203; or (c) a VH domain as in (a) and a VL domain as in (b).

31. The anti-CD3 antibody of claim 30, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 202; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 203.

32. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 202 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 203.

33. The anti-CD3 antibody of claim 8(ix), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 204; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205; or (c) a VH domain as in (a) and a VL domain as in (b).

34. The anti-CD3 antibody of claim 33, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 204; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 205.

35. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 204 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 205.

36. The anti-CD3 antibody of claim 8(x), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207; or (c) a VH domain as in (a) and a VL domain as in (b).

37. The anti-CD3 antibody of claim 36, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 206; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 207.

38. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 206 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 207.

39. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;

(b) an HVR-H2 comprising the amino acid sequence of LINPYKGVX$_1$TYX$_2$X$_3$X$_4$X$_5$KX$_6$, wherein X$_1$ is S or T; X$_2$ is N or A; X$_3$ is Q or D; X$_4$ is K or S; X$_5$ is F or V; and X$_6$ is D or G (SEQ ID NO: 183);

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

40. The anti-CD3 antibody of claim 39, wherein the binding domain is selected from the group consisting of

(i) a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28;

(ii) a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28;

and

(iii) a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

41. The anti-CD3 antibody of claim 40(i), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209; or (c) a VH domain as in (a) and a VL domain as in (b).

42. The anti-CD3 antibody of claim 41, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 208; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 209.

43. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 208 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 209.

44. The anti-CD3 antibody of claim 40(ii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211; or (c) a VH domain as in (a) and a VL domain as in (b).

45. The anti-CD3 antibody of claim 44, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 210; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 211.

46. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 210 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 211.

47. The anti-CD3 antibody of claim 40(iii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 212; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213; or (c) a VH domain as in (a) and a VL domain as in (b).

48. The anti-CD3 antibody of claim 47, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of

SEQ ID NO: 212; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 213.

49. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 212 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 213.

50. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 31;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 33;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 34;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 36.

51. The anti-CD3 antibody of claim 50, wherein the binding domain is selected from a group consisting of (i) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 214; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215; or (c) a VH domain as in (a) and a VL domain as in (b); and (ii) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 216; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 217; or (c) a VH domain as in (a) and a VL domain as in (b).

52. The anti-CD3 antibody of claim 51(i), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 214; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 215.

53. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 214 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 215.

54. The anti-CD3 antibody of claim 51(ii), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 216; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 217.

55. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 216 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 217.

56. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 37;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 38;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 40;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 41; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 42.

57. The anti-CD3 antibody of claim 56, wherein the binding domain is selected from a group consisting of (i) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 219; or (c) a VH domain as in (a) and a VL domain as in (b); and (ii) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 220; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 221; or (c) a VH domain as in (a) and a VL domain as in (b).

58. The anti-CD3 antibody of claim 57(i), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 218; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 219.

59. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 218 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 219.

60. The anti-CD3 antibody of claim 57(ii), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 220; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 221.

61. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 220 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 221.

62. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 43;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 44;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 46;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 47; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 48.

63. The anti-CD3 antibody of claim 62, wherein the binding domain is selected from a group consisting of

(i) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 223; or (c) a VH domain as in (a) and a VL domain as in (b);

(ii) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 224; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 225; or (c) a VH domain as in (a) and a VL domain as in (b); and

(iii) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 226; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227; or (c) a VH domain as in (a) and a VL domain as in (b).

64. The anti-CD3 antibody of claim 63(i), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 222; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 223.

65. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 222 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 223.

66. The anti-CD3 antibody of claim 63(ii), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of

SEQ ID NO: 224; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 225.

67. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 224 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 225.

68. The anti-CD3 antibody of claim 63(iii), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 226; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 227.

69. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 226 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 227.

70. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 49;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 50;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 51;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 52;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 54.

71. The anti-CD3 antibody of claim 70, wherein the binding domain is selected from a group consisting of

(i) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 228; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 229; or (c) a VH domain as in (a) and a VL domain as in (b); and

(ii) a binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 230; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231; or (c) a VH domain as in (a) and a VL domain as in (b).

72. The anti-CD3 antibody of claim 71(i), wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of

SEQ ID NO: 228; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 229.

73. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 228 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 229.

74. The anti-CD3 antibody of claim 71(ii), wherein the binding domain is selected from a group consisting of (a) a binding domain whereinthe VH domain comprises the amino acid sequence of SEQ ID NO: 230; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 231.

75. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 230 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 231.

76. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 55;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 56;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 57;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 59; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60.

77. The anti-CD3 antibody of claim 76, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 232; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 233; or (c) a VH domain as in (a) and a VL domain as in (b).

78. The anti-CD3 antibody of claim 77, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 232; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 233.

79. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 232 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 233.

80. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 61;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 62;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 64;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 65; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 66.

81. The anti-CD3 antibody of claim 80, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 234; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 235; or (c) a VH domain as in (a) and a VL domain as in (b).

82. The anti-CD3 antibody of claim 81, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 234; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 235.

83. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 234 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 235.

84. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 67;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 69;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 70;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 72.

85. The anti-CD3 antibody of claim 84, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 236; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 237; or (c) a VH domain as in (a) and a VL domain as in (b).

86. *The anti-CD3 antibody of claim 85, wherein the binding domain is selected from a group* consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 236; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 237.

87. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 236 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 237.

88. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 73;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 74;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 75;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 76;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 77; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78.

89. The anti-CD3 antibody of claim 88, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 238; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 239; or (c) a VH domain as in (a) and a VL domain as in (b).

90. The anti-CD3 antibody of claim 89, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 238; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 239.

91. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 238 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 239.

92. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 79;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 80;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 81;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 82;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 83; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

93. The anti-CD3 antibody of claim 92, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 240; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 241; or (c) a VH domain as in (a) and a VL domain as in (b).

94. The anti-CD3 antibody of claim 93, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 240; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 241.

95. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 240 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 241.

96. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 85;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 86;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 87;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 88;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 89; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 90.

97. The anti-CD3 antibody of claim 96, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 242; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 243; or (c) a VH domain as in (a) and a VL domain as in (b).

98. The anti-CD3 antibody of claim 97, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 242; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 243.

99. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 242 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 243.

100. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 91;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 92;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 93;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 94;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 95; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 96.

101. The anti-CD3 antibody of claim 100, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 244; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 245; or (c) a VH domain as in (a) and a VL domain as in (b).

102. The anti-CD3 antibody of claim 101, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 244; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 245.

103. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 244 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 245.

104. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 97;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 98;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 99;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 100;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 101; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 102.

105. The anti-CD3 antibody of claim 104, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 246; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 247; or (c) a VH domain as in (a) and a VL domain as in (b).

106. The anti-CD3 antibody of claim 105, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 246; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 247.

107. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 246 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 247.

108. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 103;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 104;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 105;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 106;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 107; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 108.

109. The anti-CD3 antibody of claim 108, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 248; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 249; or (c) a VH domain as in (a) and a VL domain as in (b).

110. The anti-CD3 antibody of claim109, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 248; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 249.

111. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 248 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 249.

112. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 109;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 110;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 111;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 112;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 113; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 114.

113. The anti-CD3 antibody of claim 112, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 250; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 251; or (c) a VH domain as in (a) and a VL domain as in (b).

114. The anti-CD3 antibody of claim 113, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 250; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 251.

115. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 250 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 251.

116. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 117;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 120.

117. The anti-CD3 antibody of claim 116, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 252; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 253; or (c) a VH domain as in (a) and a VL domain as in (b).

118. The anti-CD3 antibody of claim 117, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 252; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 253.

119. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 252 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 253.

120. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 121;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 122;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 123;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 124;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 125; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 126.

121. The anti-CD3 antibody of claim 120, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 254; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 255; or (c) a VH domain as in (a) and a VL domain as in (b).

122. The anti-CD3 antibody of claim 121, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 254; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 255.

123. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 254 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 255.

124. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 127;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 128;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 129;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 130;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 131; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 132.

125. The anti-CD3 antibody of claim 124, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 256; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 257; or (c) a VH domain as in (a) and a VL domain as in (b).

126. The anti-CD3 antibody of claim 125, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 256; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 257.

127. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 256 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 257.

128. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 133;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 134;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 135;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 136;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 137; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 138.

129. The anti-CD3 antibody of claim 128, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 258; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 259; or (c) a VH domain as in (a) and a VL domain as in (b).

130. The anti-CD3 antibody of claim 129, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 258; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 259.

131. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 258 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 259.

132. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 139;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 140;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 141;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 142;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 143; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 144.

133. The anti-CD3 antibody of claim 132, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 260; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 261; or (c) a VH domain as in (a) and a VL domain as in (b).

134. The anti-CD3 antibody of claim 133, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 260; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 261.

135. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 260 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 261.

136. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 145;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 146;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 147;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 148;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 149; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 150.

137. The anti-CD3 antibody of claim 136, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 262; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 263; or (c) a VH domain as in (a) and a VL domain as in (b).

138. The anti-CD3 antibody of claim 137, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 262; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 263.

139. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 262 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 263.

140. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 151;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 152;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 153;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 154;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 155; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 156.

141. The anti-CD3 antibody of claim 140, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 264; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 265; or (c) a VH domain as in (a) and a VL domain as in (b).

142. The anti-CD3 antibody of claim 141, wherein the binding domain is selected from a group consisting of (a) a binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 264; and (b) a binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 265.

143. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 264 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 265.

144. An anti-CD3 antibody, wherein the anti-CD3 antibody binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3.

145. The anti-CD3 antibody of claim 144, wherein the epitope further comprises one or more additional amino acid residues selected from the group consisting of Gln1, Asp2, and Met7 of CD3; wherein optionally the epitope comprises amino acid residues Gln1, Asp2, and Glu6 of CD3; wherein optionally the epitope comprises amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3; wherein optionally the epitope does not comprise amino acid residue Glu5 of CD3; wherein optionally the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3; and wherein optionally the epitope consists of amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

146. The anti-CD3 antibody of any one of claims 1-145, wherein the binding domain binds to a human CD3 polypeptide or a cynomolgus monkey (cyno) CD3 polypeptide.

147. The anti-CD3 antibody of claim 146, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3ε polypeptide or a cyno CD3ε polypeptide, respectively; and wherein optionally the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3γ polypeptide or a cyno CD3γ polypeptide, respectively.

148. The anti-CD3 antibody of any one of claims 1-147, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 250 nM or lower.

149. The anti-CD3 antibody of claim 148, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 100 nM or lower; wherein optionally the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 15 nM or lower; wherein optionally the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 10 nM or lower; and wherein optionally the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 5 nM or lower.

150. The anti-CD3 antibody of any one of claims 1-149, wherein the anti-CD3 antibody comprises an aglycosylation site mutation.

151. The anti-CD3 antibody of claim 150, wherein the aglycosylation site mutation is a substitution mutation; and wherein optionally the aglycosylation site mutation reduces effector function of the anti-CD3 antibody.

152. The anti-CD3 antibody of any one of claims 1-151, wherein the anti-CD3 antibody comprises a substitution mutation in the Fc region that reduces effector function; wherein optionally the substitution mutation is at amino acid residue N297, L234, L235, and/or D265 (EU numbering); wherein optionally the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A; and wherein optionally the substitution mutation is an N297G mutation.

153. The anti-CD3 antibody of any one of claims 1-152, wherein the anti-CD3 antibody is monoclonal, human, humanized, or chimeric.

154. The anti-CD3 antibody of any one of claims 1-153, selected from a group consisting of (a) an anti-CD3 antibody which is an antibody fragment that binds CD3; and (b) an anti-CD3 antibody which is a full-length antibody.

155. The anti-CD3 antibody of claim 154 (a), wherein the antibody fragment is selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and $(Fab')_2$ fragments.

156. The anti-CD3 antibody of any one of claims 1-155, wherein the anti-CD3 antibody is an IgG antibody.

157. The anti-CD3 antibody of any one of claims 1-156, selected from a group consisting of (a) an anti-CD3 antibody which is a monospecific antibody; and (b) an anti-CD3 antibody which is a multispecific antibody.

158. The anti-CD3 antibody of claim 157(b), wherein the multispecific antibody is a bispecific antibody; wherein optionally the bispecific antibody comprises a second binding domain that binds to a second biological molecule, wherein the second biological molecule is a cell surface antigen; wherein optionally the cell surface antigen is a tumor antigen; and wherein optionally the tumor antigen is selected from the group consisting of CD20, HER2, FcRH5 (Fc Receptor-like 5), and LYPD1.

159. The anti-CD3 antibody of claim 158, selected from a group consisting of

(i) an antibody wherein the tumor antigen is selected from the group consisting of CD20 and HER2;

(ii) an antibody wherein the tumor antigen is CD20 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162;

(iii) an antibody wherein the tumor antigen is FcRH5 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 163;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 164;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 165;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 166;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 168;

(iv) an antibody wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 169;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 170;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 171;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 172;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 173; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 174;

(v) an antibody wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 581;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 582;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 583;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 584;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 585; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 586;

(vi) an antibody wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 587;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 588;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 589;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 590;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 591; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 592;

and

(vii) an antibody wherein the tumor antigen is LYPD1 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 175;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 176;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 177;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 178;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 179; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 180.

160. The anti-CD3 antibody of claim 159(i), wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 266; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 267; or (c) a VH domain as in (a) and a VL domain as in (b).

161. The anti-CD3 antibody of claim 160, wherein the second binding domain is selected from a group consisting of (a) a second binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 266; and (b) a second binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 267.

162. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

163. The anti-CD3 antibody of claim 159(iii), wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 268; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 269; or (c) a VH domain as in (a) and a VL domain as in (b).

164. The anti-CD3 antibody of claim163, wherein the second binding domain is selected from a group consisting of (a) a second binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 268; and (b) a second binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 269.

165. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 268 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 269.

166. The anti-CD3 antibody of claim 159(iv), wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 270; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 271; or (c) a VH domain as in (a) and a VL domain as in (b).

167. The anti-CD3 antibody of claim 166, wherein the second binding domain is selected from a group consisting of (a) a second binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 270; and (b) a second binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 271.

168. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 270 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 271.

169. The anti-CD3 antibody of claim 159(v), wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 593; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 594; or (c) a VH domain as in (a) and a VL domain as in (b).

170. The anti-CD3 antibody of claim 169, wherein the second binding domain is selected from a group consisting of (a) a second binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 593; and (b) a second binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 594.

171. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 593 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 594.

172. The anti-CD3 antibody of claim 159(vi), wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 595; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 596; or (c) a VH domain as in (a) and a VL domain as in (b).

173. The anti-CD3 antibody of claim 172, wherein the second binding domain is selected from a group consisting of (a) a second binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 595; and (b) a second binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 596.

174. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 595 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 596.

175. The anti-CD3 antibody of claim 159(vii), wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 272; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 273; or (c) a VH domain as in (a) and a VL domain as in (b).

176. The anti-CD3 antibody of claim 175, wherein the second binding domain is selected from a group consisting of (a) a second binding domain wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 272; and (b) a second binding domain wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 273.

177. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 272 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 273.

178. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

an anti-CD20 arm comprising a second binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:159;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162.

179. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

180. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein the anti-CD3 antibody comprises an N297G substitution mutation.

181. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein (a) the anti-CD3 arm comprises T366S, L368A, Y407V, and N297G substitution mutations and (b) the anti-CD20 arm comprises T366W and N297G substitution mutations.

182. The anti-CD3 antibody of any one of claims 1-181, wherein the anti-CD3 antibody comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 ($CH1_1$) domain, a first CH2 ($CH2_1$) domain, a first CH3 ($CH3_1$) domain, a second CH1 ($CH1_2$) domain, second CH2 ($CH2_2$) domain, and a second CH3 ($CH3_2$) domain.

183. The anti-CD3 antibody of claim 182, wherein at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain; wherein optionally the $CH3_1$ and $CH3_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH3_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH3_2$ domain; and wherein optionally the $CH3_1$ and $CH3_2$ domains meet at an interface between said protuberance and cavity.

184. The anti-CD3 antibody of any one of claims 182-183, wherein the $CH2_1$ and $CH2_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH2_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH2_2$ domain; and wherein optionally the $CH2_1$ and $CH2_2$ domains meet at an interface between said protuberance and cavity.

185. The anti-CD3 antibody of any one of claims 1-184, wherein the half-life of the anti-CD3 antibody is about 7 days.

186. An isolated nucleic acid encoding the anti-CD3 antibody of any one of claims 1-185.

187. A vector comprising the isolated nucleic acid of claim 186.

188. A host cell comprising the vector of claim 187.

189. The host cell of claim 188, wherein the host cell is a mammalian cell; and wherein optionally the mammalian cell is a Chinese hamster ovary (CHO) cell.

190. The host cell of claim 188, wherein the host cell is a prokaryotic cell; and wherein optionally the prokaryotic cell is *E. coli*.

191. A method of producing the anti-CD3 antibody of any one of claims 1-185, the method comprising culturing the host cell of claim 188 in a culture medium.

192. The method of claim 191, wherein the method further comprises recovering the anti-CD3 antibody from the host cell or the culture medium.

193. An immunoconjugate comprising the anti-CD3 antibody of any one of claims 1-185 and a cytotoxic agent.

194. A composition comprising the anti-CD3 antibody of any one of claims 1-185.

195. The composition of claim 194, further comprising a pharmaceutically acceptable carrier, excipient, or diluent; wherein optionally the composition is a pharmaceutical composition; and wherein optionally the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent.

196. The anti-CD3 antibody of any one of claims 1-185 for use as a medicament.

197. Use of the anti-CD3 antibody of any one of claims 1-185 in the manufacture of a medicament for treating or delaying progression of a cell proliferative disorder or an autoimmune disorder in a subject.

198. Use of the anti-CD3 antibody of any one of claims 1-185 in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

199. The use of claim 197 or claim 198, wherein the cell proliferative disorder is a cancer; wherein optionally the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma; and wherein optionally the cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML),

chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

200. The use of claim 197 or claim 198, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

201. The use of any one of claims 197-200, wherein the anti-CD3 antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a second biological molecule located on a target cell other than the immune effector cell; wherein optionally the anti-CD3 antibody activates the immune effector cell following binding to (a) and (b); and wherein optionally the activated immune effector cell is capable of exerting a cytotoxic effect and/or an apoptotic effect on the target cell.

202. The use of any one of claims 197-201, wherein the anti-CD3 antibody is formulated for administration to the subject in a dosage of about 0.01 mg/kg to about 10 mg/kg; wherein optionally the anti-CD3 antibody is formulated for administration to the subject in a dosage of about 0.1 mg/kg to about 10 mg/kg; and wherein optionally the anti-CD3 antibody is formulated for administration to the subject in a dosage of about 1 mg/kg.

203. The use of any one of claims 197-202, wherein the medicament further comprises a PD-1 axis binding antagonist and/or an additional therapeutic agent; wherein optionally the PD-1 axis binding antagonist or additional therapeutic agent is formulated for administration prior to or subsequent to the administration of the anti-CD3 antibody; and wherein optionally the PD-1 axis binding antagonist or additional therapeutic agent is formulated for concurrent administration with the anti-CD3 antibody.

204. The use of claim 203, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist.

205. The use of claim 204, wherein the PD-1 axis binding antagonist is a PD-1 binding antagonist; wherein optionally the PD-1 binding antagonist is selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), CT-011 (pidilizumab), and AMP-224.

206. The use of claim 204, wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist; and wherein optionally the PD-L1 binding antagonist is selected from the group consisting of: YW243.55.S70, MPDL3280A, MDX-1105, and MEDI4736.

207. The use of claim 204, wherein the PD-1 axis binding antagonist is a PD-L2 binding antagonist; and wherein optionally the PD-L2 binding antagonist is an antibody or an immunoadhesin.

208. Use of an anti-CD3 antibody in the manufacture of a medicament for treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof , wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm and wherein the medicament is formulated for administration with a PD-1 axis binding antagonist.

209. Use of an anti-CD3 antibody in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm and wherein the medicament is formulated for administration with a PD-1 axis binding antagonist.

210. The use of claim 208 or 209, wherein:

(a) the anti-CD3 arm comprises a first binding domain comprising:
    (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 184, and
    (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 185; and
(b) the anti-CD20 arm comprises a second binding domain comprising:
    (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 266, and
    (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 267; and
(c) the PD-1 axis binding antagonist is an anti-PD-L1 antibody.

211. The use of any one of claims 197-210, wherein the medicament further comprises a glucocorticoid; and wherein optionally the glucocorticoid is dexamethasone.

212. The use of any one of claims 197-211, wherein the medicament further comprises a rituximab.

213. The use of any one of claims 197-211, wherein the medicament further comprises an obinutuzumab.

214. The use of any one of claims 197-213, wherein the medicament further comprises an antibody-drug conjugate (ADC).

215. The use of any one of claims 197-214, wherein the anti-CD3 antibody is formulated for administration subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally; wherein optionally the anti-CD3 antibody is formulated for administration subcutaneously; and wherein optionally the anti-CD3 antibody is formulated for administration intravenously.

216. The use of any one of claims 197-215, wherein the subject is a human.

217. A kit comprising:

(a) the composition of any one of claims 194-195; and

(b) a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder or an autoimmune disorder.

WHAT IS CLAIMED IS:

1. An anti-cluster of differentiation 3 (CD3) antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

2. The anti-CD3 antibody of claim 1, wherein the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 184; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185; or (c) a VH domain as in (a) and a VL domain as in (b).

3. The anti-CD3 antibody of claim 2, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 184.

4. The anti-CD3 antibody of claim 2, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 185.

5. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185.

6. The anti-CD3 antibody of claim 1, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 186; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187; or (c) a VH domain as in (a) and a VL domain as in (b).

7. The anti-CD3 antibody of claim 6, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 186.

8. The anti-CD3 antibody of claim 6, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 187.

9. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 186 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 187.

10. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of $X_1X_2YSX_3X_4X_5FDY$, wherein X_1 is selected from the group consisting of D, T, and S; X_2 is selected from the group consisting of G, A, and S; X_3 is R or N; X_4 is Y or A; and X_5 is Y or A (SEQ ID NO: 181);
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of $X_1X_2SX_3X_4LRT$, wherein X_1 is K or T; X_2 is Q or A; X_3 is F or A; and X_4 is I or A (SEQ ID NO: 182).

11. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

12. The anti-CD3 antibody of claim 11, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189; or (c) a VH domain as in (a) and a VL domain as in (b).

13. The anti-CD3 antibody of claim 12, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 188.

14. The anti-CD3 antibody of claim 12, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 189.

15. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 188 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 189.

16. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 13;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

17. The anti-CD3 antibody of claim 16, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 191; or (c) a VH domain as in (a) and a VL domain as in (b).

18. The anti-CD3 antibody of claim 17, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 190.

19. The anti-CD3 antibody of claim 17, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 191.

20. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 190 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 191.

21. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.

22. The anti-CD3 antibody of claim 21, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 193; or (c) a VH domain as in (a) and a VL domain as in (b).

23. The anti-CD3 antibody of claim 22, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 192.

24. The anti-CD3 antibody of claim 22, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 193.

25. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 192 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 193.

26. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 15.

27. The anti-CD3 antibody of claim 26, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 194; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 195; or (c) a VH domain as in (a) and a VL domain as in (b).

28. The anti-CD3 antibody of claim 27, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 194.

29. The anti-CD3 antibody of claim 27, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 195.

30. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 194 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 195.

31. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 16.

32. The anti-CD3 antibody of claim 31, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 197; or (c) a VH domain as in (a) and a VL domain as in (b).

33. The anti-CD3 antibody of claim 32, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 196.

34. The anti-CD3 antibody of claim 32, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 197.

35. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 196 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 197.

36. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

37. The anti-CD3 antibody of claim 36, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199; or (c) a VH domain as in (a) and a VL domain as in (b).

38. The anti-CD3 antibody of claim 37, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 198.

39. The anti-CD3 antibody of claim 37, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 199.

40. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 198 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 199.

41. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 18;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

42. The anti-CD3 antibody of claim 41, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 200; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 201; or (c) a VH domain as in (a) and a VL domain as in (b).

43. The anti-CD3 antibody of claim 42, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 200.

44. The anti-CD3 antibody of claim 42, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 201.

45. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 200 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 201.

46. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 19;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

47. The anti-CD3 antibody of claim 46, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 202; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 203; or (c) a VH domain as in (a) and a VL domain as in (b).

48. The anti-CD3 antibody of claim 47, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 202.

49. The anti-CD3 antibody of claim 47, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 203.

50. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 202 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 203.

51. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 20;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

52. The anti-CD3 antibody of claim 51, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 204; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205; or (c) a VH domain as in (a) and a VL domain as in (b).

53. The anti-CD3 antibody of claim 52, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 204.

54. The anti-CD3 antibody of claim 52, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 205.

55. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 204 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 205.

56. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22.

57. The anti-CD3 antibody of claim 56, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207; or (c) a VH domain as in (a) and a VL domain as in (b).

58. The anti-CD3 antibody of claim 57, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 206.

59. The anti-CD3 antibody of claim 57, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 207.

60. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 206 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 207.

61. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;
(b) an HVR-H2 comprising the amino acid sequence of LINPYKGVX$_1$TYX$_2$X$_3$X$_4$X$_5$KX$_6$, wherein X$_1$ is S or T; X$_2$ is N or A; X$_3$ is Q or D; X$_4$ is K or S; X$_5$ is F or V; and X$_6$ is D or G (SEQ ID NO: 183);
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

62. The anti-CD3 antibody of claim 61, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

63. The anti-CD3 antibody of claim 62, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209; or (c) a VH domain as in (a) and a VL domain as in (b).

64. The anti-CD3 antibody of claim 63, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 208.

65. The anti-CD3 antibody of claim 63, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 209.

66. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 208 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 209.

67. The anti-CD3 antibody of claim 61, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

68. The anti-CD3 antibody of claim 67, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211; or (c) a VH domain as in (a) and a VL domain as in (b).

69. The anti-CD3 antibody of claim 68, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 210.

70. The anti-CD3 antibody of claim 68, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 211.

71. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 210 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 211.

72. The anti-CD3 antibody of claim 61, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

73. The anti-CD3 antibody of claim 72, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 212; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213; or (c) a VH domain as in (a) and a VL domain as in (b).

74. The anti-CD3 antibody of claim 73, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 212.

75. The anti-CD3 antibody of claim 73, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 213.

76. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 212 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 213.

77. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 31;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 33;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 34;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 36.

78. The anti-CD3 antibody of claim 77, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 214; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215; or (c) a VH domain as in (a) and a VL domain as in (b).

79. The anti-CD3 antibody of claim 78, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 214.

80. The anti-CD3 antibody of claim 78, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 215.

81. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 214 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 215.

82. The anti-CD3 antibody of claim 77, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 216; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 217; or (c) a VH domain as in (a) and a VL domain as in (b).

83. The anti-CD3 antibody of claim 82, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 216.

84. The anti-CD3 antibody of claim 82, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 217.

85. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 216 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 217.

86. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 37;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 38;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 40;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 41; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 42.

87. The anti-CD3 antibody of claim 86, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 219; or (c) a VH domain as in (a) and a VL domain as in (b).

88. The anti-CD3 antibody of claim 87, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 218.

89. The anti-CD3 antibody of claim 87, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 219.

90. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 218 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 219.

91. The anti-CD3 antibody of claim 86, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 220; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 221; or (c) a VH domain as in (a) and a VL domain as in (b).

92. The anti-CD3 antibody of claim 91, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 220.

93. The anti-CD3 antibody of claim 91, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 221.

94. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 220 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 221.

95. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 43;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 44;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 46;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 47; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 48.

96. The anti-CD3 antibody of claim 95, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 223; or (c) a VH domain as in (a) and a VL domain as in (b).

97. The anti-CD3 antibody of claim 96, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 222.

98. The anti-CD3 antibody of claim 96, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 223.

99. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 222 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 223.

100. The anti-CD3 antibody of claim 95, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 224; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 225; or (c) a VH domain as in (a) and a VL domain as in (b).

101. The anti-CD3 antibody of claim 100, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 224.

102. The anti-CD3 antibody of claim 100, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 225.

103. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 224 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 225.

104. The anti-CD3 antibody of claim 95, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of

SEQ ID NO: 226; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227; or (c) a VH domain as in (a) and a VL domain as in (b).

105. The anti-CD3 antibody of claim 104, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 226.

106. The anti-CD3 antibody of claim 104, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 227.

107. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 226 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 227.

108. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 49;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 50;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 51;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 52;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 54.

109. The anti-CD3 antibody of claim 108, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 228; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 229; or (c) a VH domain as in (a) and a VL domain as in (b).

110. The anti-CD3 antibody of claim 109, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 228.

111. The anti-CD3 antibody of claim 109, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 229.

112. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 228 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 229.

113. The anti-CD3 antibody of claim 108, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 230; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231; or (c) a VH domain as in (a) and a VL domain as in (b).

114. The anti-CD3 antibody of claim 113, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 230.

115. The anti-CD3 antibody of claim 113, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 231.

116. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 230 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 231.

117. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 55;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 56;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 57;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 59; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60.

118. The anti-CD3 antibody of claim 117, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 232; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 233; or (c) a VH domain as in (a) and a VL domain as in (b).

119. The anti-CD3 antibody of claim 118, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 232.

120. The anti-CD3 antibody of claim 118, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 233.

121. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 232 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 233.

122. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 61;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 62;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 64;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 65; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 66.

123. The anti-CD3 antibody of claim 122, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 234; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 235; or (c) a VH domain as in (a) and a VL domain as in (b).

124. The anti-CD3 antibody of claim 123, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 234.

125. The anti-CD3 antibody of claim 123, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 235.

126. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 234 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 235.

127. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 67;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 69;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 70;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 72.

128. The anti-CD3 antibody of claim 127, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 236; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 237; or (c) a VH domain as in (a) and a VL domain as in (b).

129. The anti-CD3 antibody of claim 128, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 236.

130. The anti-CD3 antibody of claim 128, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 237.

131. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 236 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 237.

132. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 73;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 74;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 75;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 76;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 77; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78.

133. The anti-CD3 antibody of claim 132, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 238; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 239; or (c) a VH domain as in (a) and a VL domain as in (b).

134. The anti-CD3 antibody of claim 133, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 238.

135. The anti-CD3 antibody of claim 133, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 239.

136. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 238 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 239.

137. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 79;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 80;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 81;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 82;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 83; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

138. The anti-CD3 antibody of claim 137, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 240; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 241; or (c) a VH domain as in (a) and a VL domain as in (b).

139. The anti-CD3 antibody of claim 138, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 240.

140. The anti-CD3 antibody of claim 138, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 241.

141. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 240 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 241.

142. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 85;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 86;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 87;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 88;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 89; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 90.

143. The anti-CD3 antibody of claim 142, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 242; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 243; or (c) a VH domain as in (a) and a VL domain as in (b).

144. The anti-CD3 antibody of claim 143, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 242.

145. The anti-CD3 antibody of claim 143, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 243.

146. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 242 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 243.

147. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 91;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 92;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 93;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 94;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 95; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 96.

148. The anti-CD3 antibody of claim 147, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 244; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 245; or (c) a VH domain as in (a) and a VL domain as in (b).

149. The anti-CD3 antibody of claim 148, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 244.

150. The anti-CD3 antibody of claim 148, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 245.

151. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 244 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 245.

152. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 97;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 98;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 99;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 100;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 101; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 102.

153. The anti-CD3 antibody of claim 152, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 246; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 247; or (c) a VH domain as in (a) and a VL domain as in (b).

154. The anti-CD3 antibody of claim 153, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 246.

155. The anti-CD3 antibody of claim 153, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 247.

156. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 246 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 247.

157. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 103;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 104;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 105;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 106;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 107; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 108.

158. The anti-CD3 antibody of claim 157, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 248; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 249; or (c) a VH domain as in (a) and a VL domain as in (b).

159. The anti-CD3 antibody of claim 158, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 248.

160. The anti-CD3 antibody of claim 158, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 249.

161. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 248 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 249.

162. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 109;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 110;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 111;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 112;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 113; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 114.

163. The anti-CD3 antibody of claim 162, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 250; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 251; or (c) a VH domain as in (a) and a VL domain as in (b).

164. The anti-CD3 antibody of claim 163, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 250.

165. The anti-CD3 antibody of claim 163, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 251.

166. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 250 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 251.

167. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 117;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 120.

168. The anti-CD3 antibody of claim 167, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of

SEQ ID NO: 252; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 253; or (c) a VH domain as in (a) and a VL domain as in (b).

169. The anti-CD3 antibody of claim 168, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 252.

170. The anti-CD3 antibody of claim 168, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 253.

171. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 252 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 253.

172. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 121;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 122;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 123;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 124;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 125; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 126.

173. The anti-CD3 antibody of claim 172, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 254; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 255; or (c) a VH domain as in (a) and a VL domain as in (b).

174. The anti-CD3 antibody of claim 173, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 254.

175. The anti-CD3 antibody of claim 173, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 255.

176. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 254 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 255.

177. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 127;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 128;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 129;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 130;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 131; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 132.

178. The anti-CD3 antibody of claim 177, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 256; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 257; or (c) a VH domain as in (a) and a VL domain as in (b).

179. The anti-CD3 antibody of claim 178, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 256.

180. The anti-CD3 antibody of claim 178, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 257.

181. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 256 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 257.

182. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 133;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 134;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 135;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 136;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 137; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 138.

183. The anti-CD3 antibody of claim 182, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 258; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 259; or (c) a VH domain as in (a) and a VL domain as in (b).

184. The anti-CD3 antibody of claim 183, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 258.

185. The anti-CD3 antibody of claim 183, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 259.

186. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 258 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 259.

187. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 139;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 140;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 141;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 142;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 143; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 144.

188. The anti-CD3 antibody of claim 187, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 260; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 261; or (c) a VH domain as in (a) and a VL domain as in (b).

189. The anti-CD3 antibody of claim 188, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 260.

190. The anti-CD3 antibody of claim 188, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 261.

191. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 260 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 261.

192. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 145;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 146;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 147;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 148;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 149; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 150.

193. The anti-CD3 antibody of claim 192, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 262; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 263; or (c) a VH domain as in (a) and a VL domain as in (b).

194. The anti-CD3 antibody of claim 193, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 262.

195. The anti-CD3 antibody of claim 193, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 263.

196. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 262 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 263.

197. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 151;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 152;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 153;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 154;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 155; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 156.

198. The anti-CD3 antibody of claim 197, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 264; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 265; or (c) a VH domain as in (a) and a VL domain as in (b).

199. The anti-CD3 antibody of claim 198, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 264.

200. The anti-CD3 antibody of claim 198, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 265.

201. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 264 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 265.

202. An anti-CD3 antibody, wherein the anti-CD3 antibody binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3.

203. The anti-CD3 antibody of claim 202, wherein the epitope further comprises one or more additional amino acid residues selected from the group consisting of Gln1, Asp2, and Met7 of CD3.

204. The anti-CD3 antibody of claim 202 or 203, wherein the epitope comprises amino acid residues Gln1, Asp2, and Glu6 of CD3.

205. The anti-CD3 antibody of any one of claims 202-204, wherein the epitope comprises amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

206. The anti-CD3 antibody of any one of claims 202-205, wherein the epitope does not comprise amino acid residue Glu5 of CD3.

207. The anti-CD3 antibody of any one of claims 202-206, wherein the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3.

208. The anti-CD3 antibody of any one of claims 202-207, wherein the epitope consists of amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

209. The anti-CD3 antibody of any one of claims 1-208, wherein the binding domain binds to a human CD3 polypeptide or a cynomolgus monkey (cyno) CD3 polypeptide.

210. The anti-CD3 antibody of claim 209, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3ε polypeptide or a cyno CD3ε polypeptide, respectively.

211. The anti-CD3 antibody of claim 210, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3γ polypeptide or a cyno CD3γ polypeptide, respectively.

212. The anti-CD3 antibody of any one of claims 1-211, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 250 nM or lower.

213. The anti-CD3 antibody of claim 2122, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 100 nM or lower.

214. The anti-CD3 antibody of claim 213, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 15 nM or lower.

215. The anti-CD3 antibody of claim 214, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 10 nM or lower.

216. The anti-CD3 antibody of claim 215, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 5 nM or lower.

217. The anti-CD3 antibody of any one of claims 1-216, wherein the anti-CD3 antibody comprises an aglycosylation site mutation.

218. The anti-CD3 antibody of claim 217, wherein the aglycosylation site mutation is a substitution mutation.

219. The anti-CD3 antibody of claim 217 or 218, wherein the aglycosylation site mutation reduces effector function of the anti-CD3 antibody.

220. The anti-CD3 antibody of any one of claims 1-218, wherein the anti-CD3 antibody comprises a substitution mutation in the Fc region that reduces effector function.

221. The anti-CD3 antibody of claim 218 or 220, wherein the substitution mutation is at amino acid residue N297, L234, L235, and/or D265 (EU numbering).

222. The anti-CD3 antibody of claim 221, wherein the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A.

223. The anti-CD3 antibody of claim 222, wherein the substitution mutation is an N297G mutation.

224. The anti-CD3 antibody of any one of claims 1-223, wherein the anti-CD3 antibody is monoclonal, human, humanized, or chimeric.

225. The anti-CD3 antibody of any one of claims 1-224, wherein the anti-CD3 antibody is an antibody fragment that binds CD3.

226. The anti-CD3 antibody of claim 225, wherein the antibody fragment is selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and $(Fab')_2$ fragments.

227. The anti-CD3 antibody of any one of claims 1-224, wherein the anti-CD3 antibody is a full-length antibody.

228. The anti-CD3 antibody of any one of claims 1-227, wherein the anti-CD3 antibody is an IgG antibody.

229. The anti-CD3 antibody of any one of claims 1-228, wherein the anti-CD3 antibody is a monospecific antibody.

230. The anti-CD3 antibody of any one of claims 1-228, wherein the anti-CD3 antibody is a multispecific antibody.

231. The anti-CD3 antibody of claim 230, wherein the multispecific antibody is a bispecific antibody.

232. The anti-CD3 antibody of claim 231, wherein the bispecific antibody comprises a second binding domain that binds to a second biological molecule, wherein the second biological molecule is a cell surface antigen.

233. The anti-CD3 antibody of claim 232, wherein the cell surface antigen is a tumor antigen.

234. The anti-CD3 antibody of claim 233, wherein the tumor antigen is selected from the group consisting of CD20, HER2, FcRH5 (Fc Receptor-like 5), and LYPD1.

235. The anti-CD3 antibody of claim 234, wherein the tumor antigen is selected from the group consisting of CD20 and HER2.

236. The anti-CD3 antibody of claim 234, wherein the tumor antigen is CD20 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162.

237. The anti-CD3 antibody of claim 235, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 266; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 267; or (c) a VH domain as in (a) and a VL domain as in (b).

238. The anti-CD3 antibody of claim 237, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 266.

239. The anti-CD3 antibody of claim 237, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 267.

240. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

241. The anti-CD3 antibody of claim 234, wherein the tumor antigen is FcRH5 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 163;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 164;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 165;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 166;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 168.

242. The anti-CD3 antibody of claim 241, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 268; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 269; or (c) a VH domain as in (a) and a VL domain as in (b).

243. The anti-CD3 antibody of claim 242, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 268.

244. The anti-CD3 antibody of claim 242, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 269.

245. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 268 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 269.

246. The anti-CD3 antibody of claim 234, wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 169;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 170;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 171;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 172;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 173; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 174.

247. The anti-CD3 antibody of claim 246, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 270; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 271; or (c) a VH domain as in (a) and a VL domain as in (b).

248. The anti-CD3 antibody of claim 247, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 270.

249. The anti-CD3 antibody of claim 247, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 271.

250. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 270 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 271.

251. The anti-CD3 antibody of claim 234, wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 581;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 582;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 583;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 584;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 585; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 586.

252. The anti-CD3 antibody of claim 251, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 593; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 594; or (c) a VH domain as in (a) and a VL domain as in (b).

253. The anti-CD3 antibody of claim 252, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 593.

254. The anti-CD3 antibody of claim 252, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 594.

255. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 593 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 594.

256. The anti-CD3 antibody of claim 234, wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 587;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 588;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 589;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 590;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 591; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 592.

257. The anti-CD3 antibody of claim 256, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 595; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 596; or (c) a VH domain as in (a) and a VL domain as in (b).

258. The anti-CD3 antibody of claim 257, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 595.

259. The anti-CD3 antibody of claim 257, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 596.

260. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 595 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 596.

261. The anti-CD3 antibody of claim 234, wherein the tumor antigen is LYPD1 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 175;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 176;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 177;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 178;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 179; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 180.

262. The anti-CD3 antibody of claim 261, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid

sequence of SEQ ID NO: 272; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 273; or (c) a VH domain as in (a) and a VL domain as in (b).

263. The anti-CD3 antibody of claim 262, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 272.

264. The anti-CD3 antibody of claim 262, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 273.

265. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 272 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 273.

266. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

an anti-CD20 arm comprising a second binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:159;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162.

267. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

268. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of

SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein the anti-CD3 antibody comprises an N297G substitution mutation.

269. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein (a) the anti-CD3 arm comprises T366S, L368A, Y407V, and N297G substitution mutations and (b) the anti-CD20 arm comprises T366W and N297G substitution mutations.

270. The anti-CD3 antibody of any one of claims 1-269, wherein the anti-CD3 antibody comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 ($CH1_1$) domain, a first CH2 ($CH2_1$) domain, a first CH3 ($CH3_1$) domain, a second CH1 ($CH1_2$) domain, second CH2 ($CH2_2$) domain, and a second CH3 ($CH3_2$) domain.

271. The anti-CD3 antibody of claim 270, wherein at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain.

272. The anti-CD3 antibody of claim 271, wherein the $CH3_1$ and $CH3_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH3_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH3_2$ domain.

273. The anti-CD3 antibody of claim 272, wherein the $CH3_1$ and $CH3_2$ domains meet at an interface between said protuberance and cavity.

274. The anti-CD3 antibody of any one of claims 270-273, wherein the $CH2_1$ and $CH2_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH2_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH2_2$ domain.

275. The anti-CD3 antibody of claim 274, wherein the $CH2_1$ and $CH2_2$ domains meet at an interface between said protuberance and cavity.

276. The anti-CD3 antibody of any one of claims 1-275, wherein the half-life of the anti-CD3 antibody is about 7 days.

277. An isolated nucleic acid encoding the anti-CD3 antibody of any one of claims 1-276.

278. A vector comprising the isolated nucleic acid of claim 277.

279. A host cell comprising the vector of claim 278.

280. The host cell of claim 279, wherein the host cell is a mammalian cell.

281. The host cell of claim 280, wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.

282. The host cell of claim 281, wherein the host cell is a prokaryotic cell.

283. The host cell of claim 282, wherein the prokaryotic cell is *E. coli*.

284. A method of producing the anti-CD3 antibody of any one of claims 1-276, the method comprising culturing the host cell of claim 279 in a culture medium.

285. The method of claim 284, wherein the method further comprises recovering the anti-CD3 antibody from the host cell or the culture medium.

286. An immunoconjugate comprising the anti-CD3 antibody of any one of claims 1-276 and a cytotoxic agent.

287. A composition comprising the anti-CD3 antibody of any one of claims 1-276.

288. The composition of claim 287, further comprising a pharmaceutically acceptable carrier, excipient, or diluent.

289. The composition of claim 288, wherein the composition is a pharmaceutical composition.

290. The composition of any one of claims 287-289, wherein the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent.

291. The anti-CD3 antibody of any one of claims 1-276 for use as a medicament.

292. The anti-CD3 antibody of any one of claims 1-276 for use in treating or delaying progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof.

293. The anti-CD3 antibody of any one of claims 1-276 for use in enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

294. The anti-CD3 antibody of claim 292 or claim 293, wherein the cell proliferative disorder is a cancer.

295. The anti-CD3 antibody of claim 294, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

296. The anti-CD3 antibody of claim 295, wherein the cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

297. The anti-CD3 antibody of claim 292 or claim 293, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

298. Use of the anti-CD3 antibody of any one of claims 1-276 in the manufacture of a medicament for treating or delaying progression of a cell proliferative disorder or an autoimmune disorder.

299. Use of the anti-CD3 antibody of any one of claims 1-276 in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

300. The use of claim 298 or claim 299, wherein the cell proliferative disorder is a cancer.

301. The use of claim 300, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

302. The use of claim 301, wherein the cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

303. The use of claim 298 or claim 299, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

304. A method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject the anti-CD3 antibody of any one of claims 1-276.

305. A method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject an effective amount of the anti-CD3 antibody of any one of claims 1-276.

306. The method of claim 304 or claim 305, wherein the cell proliferative disorder is a cancer.

307. The method of claim 306, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

308. The method of claim 307, wherein the cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

309. The method of claim 304 or claim 305, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

310. The method of any one of claims 304-309, wherein the anti-CD3 antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a second biological molecule located on a target cell other than the immune effector cell.

311. The method of claim 310, wherein the anti-CD3 antibody activates the immune effector cell following binding to (a) and (b).

312. The method of claim 311, wherein the activated immune effector cell is capable of exerting a cytotoxic effect and/or an apoptotic effect on the target cell.

313. The method of any one of claims 304-312, wherein the anti-CD3 antibody is administered to the subject in a dosage of about 0.01 mg/kg to about 10 mg/kg.

314. The method of claim 313, wherein the anti-CD3 antibody is administered to the subject in a dosage of about 0.1 mg/kg to about 10 mg/kg.

315. The method of claim 314, wherein the anti-CD3 antibody is administered to the subject in a dosage of about 1 mg/kg.

316. The method of any one of claims 304-315, further comprising administering to the subject a PD-1 axis binding antagonist and/or an additional therapeutic agent.

317. The method of claim 316, wherein the PD-1 axis binding antagonist or additional therapeutic agent is administered prior to or subsequent to the administration of the anti-CD3 antibody.

318. The method of claim 317, wherein the PD-1 axis binding antagonist additional therapeutic agent is administered concurrently with the anti-CD3 antibody.

319. The method of any one of claims 316-318, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist.

320. The method of claim 319, wherein the PD-1 axis binding antagonist is a PD-1 binding antagonist.

321. The method of claim 320, wherein the PD-1 binding antagonist is selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), CT-011 (pidilizumab), and AMP-224.

322. The method of claim 319, wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist.

323. The method of claim 322, wherein the PD-L1 binding antagonist is selected from the group consisting of: YW243.55.S70, MPDL3280A, MDX-1105, and MEDI4736.

324. The method of claim 319, wherein the PD-1 axis binding antagonist is a PD-L2 binding antagonist.

325. The method of claim 324, wherein the PD-L2 binding antagonist is an antibody or an immunoadhesin.

326. A method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm.

327. A method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm.

328. The method of claim 326 or 327, wherein:

(a) the anti-CD3 arm comprises a first binding domain comprising:
    (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 184, and
    (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 185; and
(b) the anti-CD20 arm comprises a second binding domain comprising:
    (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 266, and
    (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 267; and
(c) the PD-1 axis binding antagonist is an anti-PD-L1 antibody.

329. The method of any one of claims 304-328, further comprising administering to the subject a glucocorticoid.

330. The method of claim 329, wherein the glucocorticoid is dexamethasone.

331. The method of any one of claims 304-330, further comprising administering to the subject rituximab.

332. The method of any one of claims 304-330, further comprising administering to the subject obinutuzumab.

333. The method of any one of claims 304-332, further comprising administering to the subject an antibody-drug conjugate (ADC).

334. The method of any one of claims 304-333, wherein the anti-CD3 antibody is administered subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.

335. The method of claim 334, wherein the anti-CD3 antibody is administered subcutaneously.

336. The method of claim 335, wherein the anti-CD3 antibody is administered intravenously.

337. The method of any one of claims 304-336, wherein the subject is a human.

338. A kit comprising:

(a) the composition of any one of claims 287-290; and

(b) a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder or an autoimmune disorder.